Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C

Conjeevaram HS, Wahed AS, Afdhal NH, Howell CD, Everhart JE, Hoofnagle JH, et al. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology. 2011;140(2):469-477.

Publication Type:

Journal Article

Authors:

Conjeevaram, H.S.; Wahed, A.S.; N H Afdhal; Howell, C.D.; Everhart, J.E.; Hoofnagle, J.H.; Virahep-C study group

Source:

Gastroenterology, Volume 140, Issue 2, p.469-477 (2011)

Keywords:

Adult, Age Factors, Antiviral Agents, Body Mass Index, Body Weight, Clinical Trials as Topic, Disease, drug effects, drug therapy, Drug Therapy,Combination, Fasting, Female, Fibrosis, Gastroenterology, Genotype, genotype 1, Glucose, HCV, Hepacivirus, hepatitis, Hepatitis C, hepatitis C virus, Hepatitis C,Chronic, Homeostasis, Humans, Infection, Insulin, Insulin Resistance, interferon, Interferon Alfa-2a, Interferon-alpha, Liver, Male, methods, Michigan, Multicenter Studies, Multicenter Studies as Topic, Patients, peginterferon, Polyethylene Glycols, Prevalence, Proteins, Recombinant Proteins, Research, Research Support, resistance, Ribavirin, Role, sustained virologic response, SVR, therapeutic use, therapy, Time, treatment, Universities

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/21070775

Export Citation:

RIS Format

Top